Calypso Biotech BV

Pharma Breaks Bread With Trump And RFK Jr But Will They Butt Heads? Donald Trump’s second term as US president does not begin until 20 January but pharma executives spent much of last year wondering w

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi

A Tall Order For The Pace Of M&A December was a red-letter month for biotechnology companies as the large number of acquisitions that were ether completed or announced propelled the NASDAQ Biotech Ind

Novartis Debuts Two Deals While Johnson & Johnson had the day’s largest acquisition with the $2bn offer for antibody-drug conjugate specialist Ambrx, Inc. (Also see " J&J Makes Its Biggest